CITA Biomedical Receives Standard & Poor's Approval For Listing in Its Comprehensive Market Access Program.

Business Editors

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Oct. 16, 2000

CITA Biomedical Inc. (OTCBB:DTOX), a growing leader in the addiction treatment and recovery industry, today announced that the Editorial Board of Standard & Poor's has approved the company for inclusion in its premier Market Access Program.

A full description of CITA will now be published in the Daily News Section of Standard Corporation Records. As part of the program, Standard & Poor's also will initiate financial coverage for CITA Biomedical on the Standard & Poor's Internet site http://www.advisorinsight.com/pub/maccess/otcbb/DTOX_125558.htm as well as S&P MarketScope and the S&P Stock Guide database.

"S&P's financial coverage program is one of the industry's best programs to broaden the dissemination of company information and heighten awareness of CITA in the professional investment community," said Joseph V. Dunn, the company's president & CEO. "We consider participation in this program another important step in expanding our outreach program to current and potential investors."

The Standard Corporation Records, the definitive source of financial information available in print, CD-ROM and on the Internet, is a recognized securities manual for secondary trading in approximately 35 states under the Blue Sky Laws. Standard & Poor's Web site www.advisorinsight.com provides free access to a full spectrum of investors interested in getting information on CITA Biomedical.

Standard & Poor's MarketScope is a real-time information service offering instant access to current market information on CITA by more than 74,000 brokers and traders worldwide. Standard & Poor's Stock Guide database is distributed electronically to virtually all major quote vendors. Vital statistics such as price, volume, dividends, shares outstanding, financial position, earnings and much more will be made available to more than 240,000 brokers, traders and other investment professionals.

CITA Biomedical currently is conducting its Ultra Rapid Opiate Detoxification (UROD) programs in four major metropolitan hospitals, located in Chicago, Los Angeles, Phoenix, and Portland, Ore. Over the next several years that number is expected to triple, as the company plans to bring the procedure to an additional 10 hospitals. The company also intends to expand its scope to treat most addictions, including drugs, behavioral and alcohol, many of which will be facilitated through its wholly owned subsidiary, www.cubecentral.com. CITA also is actively exploring acquisition candidates that have a focus on the treatment of addiction. Further information on CITA Biomedical is available at www.citabio.com.

This news release contains forward-looking statements regarding the company and its businesses. These forward-looking statements are based largely on the company's expectations and are subject to a number of risks and uncertainties, some of which are beyond the company's control. The company undertakes no obligation to publicly release the results of any revision to these forward-looking statements that maybe made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.